Prostate Cancer Clinical Trials in Boston, Massachusetts

40 studies are recruiting for prostate cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

  1. Jump: MR Simulation For Radiation Therapy Master Protocol

    This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham and Women Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Brigham and Women's Hospital

    See if you can join NCT04545957 on ClinicalTrials.gov

  2. Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

    The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance. The name of the study intervention involved in th…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Locations
    4 in total
    Run by
    Fred Hutchinson Cancer Center

    See if you can join NCT05918263 on ClinicalTrials.gov

  3. Androgen-responsive POSLUMA-guided Intra-prostatic Boost

    This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target rem…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    4 in total
    Run by
    Martin T. King, MD, PhD

    See if you can join NCT07393867 on ClinicalTrials.gov

  4. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  5. Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

    This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients are counseled on post-operative pain management and then ma…

    Stage
    Phase 3
    Ages
    45 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Brigham and Women's Hospital

    See if you can join NCT07427043 on ClinicalTrials.gov

  6. Clinical Trial of Approaches to Prostate Cancer Surgery

    This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have simil…

    Stage
    Not phased
    Ages
    40 to 80
    Site
    Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts
    Locations
    9 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05155501 on ClinicalTrials.gov

  7. Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

    This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizuma…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    4 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT04946370 on ClinicalTrials.gov

  8. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Locations
    3 in total
    Run by
    Zumutor Biologics Inc.

    See if you can join NCT06451497 on ClinicalTrials.gov

  9. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  10. Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

    The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Brigham and Women's Hospital

    See if you can join NCT06099093 on ClinicalTrials.gov

  11. The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

    Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and whi…

    Stage
    Not phased
    Ages
    55 to 69
    Site
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
    Run by
    VA Office of Research and Development

    See if you can join NCT05926102 on ClinicalTrials.gov

  12. Stereotactic Magnetic Resonance Guided Radiation Therapy

    This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham & Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04115254 on ClinicalTrials.gov

  13. Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

    The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. …

    Stage
    Not phased
    Ages
    40 to 69
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    5 in total
    Run by
    Adam S. Kibel, MD

    See if you can join NCT06398639 on ClinicalTrials.gov

  14. ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

    This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 clinical centers (100 participants per center). The current standard MRI technique for prostate cancer…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    5 in total
    Run by
    University of California, San Diego

    See if you can join NCT06579417 on ClinicalTrials.gov

  15. Prostate Cancer Genetic Risk Evaluation and Screening Study

    This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population …

    Stage
    Not phased
    Ages
    35 to 74
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Run by
    Massachusetts General Hospital

    See if you can join NCT05129605 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.